首页> AIDS (London, England)> A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.

导出 OA

翻译打印收藏纠错

第一作者： Marissa,Wilck

第一单位： Merck & Co., Inc., Rahway, New Jersey, USA.

作者： Marissa,Wilck ^[1] ; Shaun,Barnabas ^[2] ; Kulkanya,Chokephaibulkit ^[3] ; Avy,Violari ^[4] ; Pope,Kosalaraksa ^[5] ; Svitlana,Yesypenko ^[6] ; Iryna,Chukhalova ^[7] ; Ron,Dagan ^[8] ; Peter,Richmond ^[9] ; Elena,Mikviman ^[1] ; Leslie,Morgan ^[1] ; Kristen,Feemster ^[1] ; Robert,Lupinacci ^[1] ; Joseph,Chiarappa ^[1] ; Shabir A,Madhi ^[10] ; Kara,Bickham ^[1] ; Luwy,Musey ^[1] ; V114-030 Study Group

作者单位： Merck & Co., Inc., Rahway, New Jersey, USA. ^[1] Department of Paediatrics, University of Stellenbosch, Cape Town, South Africa. ^[2] Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. ^[3] Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. ^[4] Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. ^[5] Odesa Regional Center for Socially Significant Diseases, Odeska Oblast. ^[6] Dnipropetrovsk Regional Medical Center Of Socially Significant Diseases, Dnipro, Ukraine. ^[7] The Shraga Segal Department of Microbiology, Immunology and Genetics Faculty of Health Sciences of the Ben-Gurion University of the Negev Beer-Sheva, Israel. ^[8] University of Western Australia, Perth, Australia. ^[9] South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. ^[10]